Axel Grothey

Campbell Clinic

Full Professor(heuristic)

Colorectal Cancer Treatments and Studies · Oncology

h-index76

i10-index238

Publications583

Citations37,784

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 9 of 9

Abstract 6516: Novel liquid biopsy epigenomic molecular tumor typing in carcinoma of unknown primary (CUP)
Cancer Research · 2026-04-03
Potential impact of non-exonuclease POLE and POLD1 mutations on high and ultrahigh TMB across cancers.
Journal of Clinical Oncology · 2025-05-28 · 2 citations
Immunotherapy in patients with early-stage microsatellite instable (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) treated in a community setting.
Journal of Clinical Oncology · 2025-05-28 · 1 citations
523: CIRCULATING TUMOR DNA FOR DETECTION OF MOLECULAR RESIDUAL DISEASE (MRD) IN PATIENTS (PTS) WITH STAGE II/III COLORECTAL CANCER (CRC): FINAL ANALYSIS OF THE BESPOKE CRC SUB COHORT
Gastroenterology · 2025-05-01
Abstract 496: Clinical, biologic, and immunogenic characteristics of gastro-esophageal cancers (GEC) harboring CLDN18::ARHGAP fusions
Cancer Research · 2025-04-21
Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.
Journal of Clinical Oncology · 2025-01-27 · 10 citations
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Nature Communications · 2025-01-15
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Nature Communications · 2024-11-25 · 27 citations
Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2024-09-23 · 2 citations

Open author page on OpenAlex →